CTOs on the Move

Bellerophon Therapeutics

www.bellerophon.com

 
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bellerophon Therapeutics raised $43.7M on 05/18/2020

Similar Companies

DNA Diagnostics Center

DNA Diagnostics Center is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.

Ostioporsis Imaging Ctr/Breast

Ostioporsis Imaging Ctr/Breast is a Palm Harbor, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strateos

Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery.

Mirati

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet medical need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati`s vision is to unlock the science behind the promise of a life beyond cancer.